TUKYSA (tucatinib)

SELF ADMINISTRATION

Indications for Prior Authorization:
  • Indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting
Patients must meet the following criteria for the indication(s) above:
  • Patient has a diagnosis of advanced, unresectable, or metastatic HER2-positive breast cancer as confirmed by chart note documentation, AND
  • Prescribed by or in consultation with an oncologist, AND
  • Patient has received one or more prior anti-HER2-based regimens in the metastatic setting, AND
  • Tukysa™ will be used in combination with trastuzumab and capecitabine
Reauthorization Criteria:
  • Patient had a positive response to therapy as confirmed by specialist chart note documentation
Dosing:
  • 300 mg taken orally twice daily
  • Severe Hepatic Impairment: 200 mg orally twice daily
  • Tukysa™ should not be used in combination with strong CYP3A inducers or moderate CYP2C8 inducers
  • If concomitant use with strong CYP2C8 inhibitors cannot be avoided, reduce Tukysa™ dose
  • Avoid concomitant use with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities
  • Consider reducing the dose of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities
Approval:

1 year

 

Last review date: August 18, 2020

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone